EFFEXOR TABLETS, 50MG

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)

Pieejams no:

WYETH CANADA

ATĶ kods:

N06AX16

SNN (starptautisko nepatentēto nosaukumu):

VENLAFAXINE

Deva:

50MG

Zāļu forma:

TABLET

Kompozīcija:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 50MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0131294003; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2004-08-19

Produkta apraksts

PRODUCT MONOGRAPH
Pr
EFFEXOR
®
(Venlafaxine Hydrochloride)
Tablets
Pr
EFFEXOR
®
XR
(Venlafaxine Hydrochloride)
Extended Release Capsules
ANTIDEPRESSANT/ANXIOLYTIC
WYETH CANADA
DATE OF PREPARATION:
MONTREAL, CANADA
July 18, 1994
Control Number:
DATE OF REVISION:
094122
November 16, 2004
THIS PRODUCT MONOGRAPH IS THE EXCLUSIVE PROPERTY OF WYETH
CANADA AND CANNOT BE REFERENCED, PUBLISHED OR COPIED WITHOUT
THE WRITTEN APPROVAL OF WYETH CANADA.
©Wyeth Canada
2
EFFEXOR/EFFEXOR XR
(Venlafaxine HCl)
PRODUCT MONOGRAPH
TABLE OF CONTENTS
PAGE
ACTIONS AND CLINICAL PHARMACOLOGY . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . 4
INDICATIONS AND CLINICAL USE . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . 16
CONTRAINDICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . .
18
WARNINGS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
PRECAUTIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Discontinuation Symptoms
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . 28
Use in Pregnancy, Labour and Delivery, and in Nursing Mothers
. . . . . . . . . . . . . . . . . 36
Paediatric Use
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . 38
Use in the Elderly
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . 38
Drug Interactions . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Drug Abuse and Dependence . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . 47
ADVERSE